Drug firm Suven Life Sciences has been granted a patent each by Canada, Europe and Hong Kong for a drug used in the treatment of neuro-degenerative diseases.
In a BSE filing today, Suven Life said, “the grant of one product patent from Canada, one product patent from Europe and one product patent from Hong Kong corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.”
Patents are valid through 2030, 2032 and 2032 respectively.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life CEO Venkat Jasti said.
With these new patents, Suven has a total of 24 granted patent from Canada, 22 from Europe and 21 from Hong Kong.
“These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II,” Suven said.
Suven Life Sciences shares were trading 2.35 per cent up at Rs 196.10 on BSE.